CN101969987A - 长散布核元件多肽组合物及其使用方法 - Google Patents

长散布核元件多肽组合物及其使用方法 Download PDF

Info

Publication number
CN101969987A
CN101969987A CN2008801164478A CN200880116447A CN101969987A CN 101969987 A CN101969987 A CN 101969987A CN 2008801164478 A CN2008801164478 A CN 2008801164478A CN 200880116447 A CN200880116447 A CN 200880116447A CN 101969987 A CN101969987 A CN 101969987A
Authority
CN
China
Prior art keywords
line
polypeptide
subject
cells
subject line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801164478A
Other languages
English (en)
Chinese (zh)
Inventor
D·尼克松
K·加里森
D·梅克勒约翰
M·奥斯特洛夫斯基
R·B·琼斯
A·阿格拉沃尔
F·M·赫克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
University of California San Diego UCSD
Original Assignee
J David Gladstone Institutes
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes, University of California San Diego UCSD filed Critical J David Gladstone Institutes
Publication of CN101969987A publication Critical patent/CN101969987A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
CN2008801164478A 2007-09-20 2008-09-19 长散布核元件多肽组合物及其使用方法 Pending CN101969987A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97399307P 2007-09-20 2007-09-20
US60/973,993 2007-09-20
PCT/US2008/010883 WO2009038756A2 (en) 2007-09-20 2008-09-19 Long interspersed nuclear element polypeptide compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CN101969987A true CN101969987A (zh) 2011-02-09

Family

ID=40468692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801164478A Pending CN101969987A (zh) 2007-09-20 2008-09-19 长散布核元件多肽组合物及其使用方法

Country Status (11)

Country Link
US (1) US20110046042A1 (https=)
EP (1) EP2200637A4 (https=)
JP (1) JP2010539901A (https=)
KR (1) KR20100075483A (https=)
CN (1) CN101969987A (https=)
AU (1) AU2008301888A1 (https=)
BR (1) BRPI0817209A2 (https=)
CA (1) CA2700115A1 (https=)
MX (1) MX2010003110A (https=)
RU (1) RU2010115088A (https=)
WO (1) WO2009038756A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
WO2011005587A1 (en) * 2009-06-24 2011-01-13 University Of Dubuque Vaccine compositions and methods of use to protect against infectious disease
EP2625292B1 (en) * 2010-10-07 2018-12-05 The General Hospital Corporation Biomarkers of cancer
WO2014004945A1 (en) * 2012-06-28 2014-01-03 University Of Louisville Research Foundation, Inc. Use of protein line-1 orf-1 as a biomarker for cancer
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
JP6830660B2 (ja) * 2015-04-03 2021-02-17 国立大学法人京都大学 がんの治療薬のスクリーニング方法
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
AU2020365129A1 (en) * 2019-10-16 2022-05-05 King Abdullah University Of Science And Technology Methods for modulating human L1 retrotransposons RNA and compositions for use therein
US20230053473A1 (en) * 2019-12-26 2023-02-23 The Johns Hopkins University Enhancing expression of line-1 encoded orf2p for cancer therapeutics
JP7569054B2 (ja) 2020-06-02 2024-10-17 学校法人東京女子医科大学 Ｓ１００ａ８阻害ペプチドとこれを含む疾患治療薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280108A (en) * 1991-09-27 1994-01-18 United States Of America Antibodies to p40
DE69637571D1 (de) * 1995-10-20 2008-08-07 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
CN1315379A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人L1因子p40蛋白12和编码这种多肽的多核苷酸
CN1315332A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——l1－12和编码这种多肽的多核苷酸
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
CN1339478A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸
CN1339450A (zh) * 2000-08-21 2002-03-13 上海博德基因开发有限公司 一种新的多肽——转座元蛋白14.41和编码这种多肽的多核苷酸
CN1343776A (zh) * 2000-09-19 2002-04-10 上海博德基因开发有限公司 一种新的多肽——dna聚合酶9.02和编码这种多肽的多核苷酸
CN1352094A (zh) * 2000-11-06 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人l1元件类蛋白19.80和编码这种多肽的多核苷酸
CN1425684A (zh) * 2001-12-19 2003-06-25 复旦大学 一种多肽——人反转录转座40蛋白－12.76和编码这种多肽的多核苷酸
AU2003294236A1 (en) * 2002-10-25 2004-05-25 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
US9267932B2 (en) * 2003-05-28 2016-02-23 The Johns Hopkins University Synthetic mammalian retrotransposon gene

Also Published As

Publication number Publication date
EP2200637A4 (en) 2011-10-19
JP2010539901A (ja) 2010-12-24
WO2009038756A2 (en) 2009-03-26
KR20100075483A (ko) 2010-07-02
AU2008301888A1 (en) 2009-03-26
MX2010003110A (es) 2010-05-19
RU2010115088A (ru) 2011-10-27
BRPI0817209A2 (pt) 2015-03-10
EP2200637A2 (en) 2010-06-30
WO2009038756A3 (en) 2009-05-14
CA2700115A1 (en) 2009-03-26
US20110046042A1 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
CN101969987A (zh) 长散布核元件多肽组合物及其使用方法
US20130323279A1 (en) Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof
US20230083931A1 (en) Coronavirus vaccines and methods of use
CN100560720C (zh) 将外源蛋白递送到胞质溶胶中的方法,及其用途
TW201329100A (zh) 有效控制豬繁殖及呼吸症候群之合成胜肽標記疫苗與檢測系統
CN115715199A (zh) 冠状病毒疫苗
WO2023049272A1 (en) Coronavirus vaccines and methods of use
Kameoka et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular α antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop
JP2010506926A (ja) Ｉｉ−Ｋｅｙ増強ワクチンの効力
Becker et al. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant
US9474793B2 (en) Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
US9486518B2 (en) Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine
US9572873B2 (en) Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
US20050196411A1 (en) Immunogenic HIV compositions and related methods
US20090041760A1 (en) Retroviral immunotherapy
WO2022236301A1 (en) Vaccines against coronavirus and methods of use
HK1135023A (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20240277829A1 (en) Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
JP2018528974A (ja) ヒトおよびネコにおけるワクチンのためのｈｉｖ、ｓｉｖおよびｆｉｖの交差反応性ｔ細胞エピトープ
KR20070019635A (ko) 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110209